Protocol Ledger

NCT07783425 · Phase III · RECRUITING

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

Interventional Phase III clinical trial protocol NCT07783425 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-24 Enrollment: 1,375 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07783425
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,375 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07783425
Protocol FieldVerified Registry Value
NCT IdentifierNCT07783425
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,375 participants (ESTIMATED)
Registered Start Date2026-08-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07783425
Hospital Research SiteLocationSite Profile
Marvel Clinical ResearchHuntington Beach, CAOpen Hospital Dossier ->
Dawes Fretzin Clinical Research Group, LLCIndianapolis, INOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI